5-氮杂-2"-脱氧胞嘧啶核苷通过抑制大鼠原代肾肌成纤维细胞 Epo基因启动子高甲基化逆转PMT
作者:
作者单位:

天津市医药科学研究所

中图分类号:

R572

基金项目:

天津市卫生健康科技项目(No. TJWJ2022MS050)


5-aza-2 "-deoxycytosine reverses PMT by inhibiting Epo gene promoter hypermethylation in rat primary renal myoblasts______________________________________________________________
Author:
Affiliation:

1.Tianjin Institute of Medical &2.Pharmaceutical Sciences

Fund Project:

Tianjin Health Research Project (Grant No: TJWJ2022MS050)

  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献 [17]
  • |
  • 相似文献
  • | | |
  • 文章评论
    摘要:

    目的 观察去甲基化剂5-氮杂-2′-脱氧胞苷(5-Aza-2"-deoxycytidine,5-Aza-CdR)对大鼠原代肾肌成纤维细胞的周细胞肌成纤维细胞转化(pericyte-myofibroblast transition,PMT)的影响。方法 5-Aza-CdR 250 ng/ml处理大鼠原代肾肌成纤维细胞72h,采用焦磷酸测序方法检测Epo启动子甲基化程度,采用免疫荧光与Western blot检测α-SMA、PDGFRβ和DNA甲基转移酶(DNMT3a)的蛋白表达水平,并检测细胞上清液EPO水平。结果 与对照组相比,5-Aza-CdR 处理能显著降低Dnmt3a的表达和EPO启动子高甲基化水平,并随之降低了肌成纤维细胞中α-SMA的表达及α-SMA与PDGFRβ的表达比例,同时,5-Aza-CdR 处理提高了细胞上清液中EPO的水平。结论 5-Aza-CdR可通过抑制大鼠原代肾肌成纤维细胞Epo启动子高甲基化逆转PMT。

    Abstract:

    Objective To observe the effect of demethylating agent 5-aza-2 "-deoxycytidine (5-Aza-CdR) on pericyte-myofibroblast transition(PMT)of primary rat renal myofibroblast. Methods Rat primary renal myofibroblast were treated with 5-Aza-CdR 250 ng/ml for 72h, and the methylation degree of Epo promoter was detected by pyrosequencing. The protein expression levels of α-SMA, PDGFRβ and DNA methyltransferase (DNMT3a) were detected by immunofluorescence and Western blot, and EPO levels in the supernatant were detected. Results Compared with control group, 5-Aza-CdR treatment significantly decreased the expression of Dnmt3a and the hypermethylation level of Epo promoter, and subsequently decreased the expression of α-SMA and the expression ratio of α-SMA to PDGFRβ in myofibroblast. Meanwhile, 5-Aza-CdR treatment increased the level of EPO in the cell supernatant. Conclusions 5-Aza-CdR can reverse PMT by inhibiting Epo promoter hypermethylation in primary renal myofibroblast.

    参考文献
    [1] Pan SY, Tsai PZ, Chou YH, et al. Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not kidney fibrosis. Kidney Int, 2021, 99(6):1354-1368. doi: 10.1016/j.kint.2021.01.017.
    [2] Stasi A, Franzin R, Divella C, et al. Double Labeling of PDGFR-β and α-SMA in Swine Models of Acute Kidney Injury to Detect Pericyte-to-Myofibroblast Transdifferentation as Early Marker of Fibrosis. Bio Protoc, 2020, 10(19):e3779. doi: 10.21769/BioProtoc.3779.
    [3] Bapst AM, Kn?pfel T, Nolan KA, et al. Neurogenic and pericytic plasticity of conditionally immortalized cells derived from renal erythropoietin-producing cells. J Cell Physiol, 2022, 237(5):2420-2433. doi: 10.1002/jcp.30677.
    [4] Lim JH, Yook JM, Oh SH, et al. Paricalcitol Improves Hypoxia-Induced and TGF-β1-Induced Injury in Kidney Pericytes[J]. Int J Mol Sci, 2021, 22(18): 9751. doi: 10.3390/ijms22189751.
    [5] Yu-Hsiang Chou, Szu-Yu Pan, Yu-Han Shao, et al. Methylation in pericytes after acute injury promotes chronic kidney disease[J]. J Clin Invest,S2020,S130(9): 4845–4857.S
    [6] Xu C, Hong Q, Zhuang K, et al. Regulation of pericyte metabolic reprogramming restricts the AKI to CKD transition. Metabolism, 2023, 145:155592. doi: 10.1016/j.metabol.2023.155592.
    [7] Chou YH, Pan SY, Shih HM, Lin SL. Update of pericytes function and their roles in kidney diseases[J]. J Formos Med Assoc, 2024, 123(3):307-317. doi: 10.1016/j.jfma.2023.08.002.
    [8] Dewi FR, Fatchiyah F. Methylation impact analysis of erythropoietin (EPO) gene to hypoxia inducible factor-1alpha (HIF-1α) activity[J]. Bioinformation, 2013, 9(15):782–787. doi: 10.6026/97320630009782.
    [9] Adomako A, Calvo V, Biran N, et al. Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment. BMC Cancer, 2015, 30,15:444. doi: 10.1186/s12885-015-1460-1.
    [10] Souma T, Yamazaki S, Moriguchi T, et al. Plasticity of renal erythropoietin-producing cells governs fibrosis[J]. J Am Soc Nephrol, 2013, 24(10):1599-616.
    [11] Asada N, Takase M, Nakamura J, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice[J]. The Journal of clinical investigation, 2011, 121(10):3981-3990. doi: 10.1172/JCI57301.S
    [12] Montesinos P, Recher C, Vives S, et al. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. N Engl J Med, 2022, 386(16):1519-1531. doi: 10.1056/NEJMoa2117344.
    [13] 郭怀鹏,康蕾,刘聪,等. 去甲基化药物治疗老年急性髓系白血病的 Meta分析[J]. 临床血液学杂志, 2021, 34(5):347-352.GUO HP, KANG L, LIU C, et al. Hypomethylating agents in elderly patients with acute myeloid leukemia: a Meta - analysis of randomised trials[J]. J Clin Hemato, 2021, 34(5):347-352.
    [14] SANTI D V,GARRETT C E,BARR P J. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs[J]. Cell,1983,33(1):9-10. doi:10.1016/0092-8674(83) 90327-6.
    [15] Christman JK. 5-Azacytidine and 5-aza-2''-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy[J]. Oncogene, 2002, 12;21(35):5483-95. doi: 10.1038/sj.onc.1205699.
    [16] Tsai HC, Li H, Van Neste L,Set al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells[J]. Cancer Cell, 2012, 21(3):430–446. doi: 10.1016/j.ccr.2011.12.029.S
    [17] Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood, 2004,103(5):1635–1640. doi: 10.1182/blood-2003-03-0687.
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2024-05-08
  • 最后修改日期:2024-09-10
  • 录用日期:2025-02-19
防诈骗提示!请勿点击不明链接或添加个人微信。编辑部所有邮箱后缀均为@cnilas.org
关闭